Oral estradiol-17 beta raises the level of plasma high-density lipoprotein in menopausal women by slowing down its clearance rate.
Plasma lipoprotein composition, plasma kinetics of autologous [125I]HDL and the metabolism of iv administered radioactively labelled artificial chylomicrons were studied in postmenopausal women during a control period and after 4 months of oral estradiol-17 beta treatment (1 mg/m2 body surface per day). Drug treatment significantly raised plasma HDL-cholesterol levels (19%) in the fasting state and total apolipoprotein A-I (16%), but did not interfere with triglyceride, VLDL, LDL or apolipoprotein-B values. As compared with the control period, estradiol-17 beta administration significantly slowed down plasma [125I]HDL clearance by about 82% and reduced the delipidation index of the injected artificial chylomicrons by 47% as a consequence of impaired plasma lipolytic activity.
Quintão
E C
EC
Lipid Metabolism Unit, Hospital of the University of São Paulo Medical School, Brazil.
Nakandakare
E
E
Oliveira
H C
HC
Rocha
J C
JC
Garcia
R C
RC
de Melo
N R
NR
D000284:Administration, Oral; D002914:Chylomicrons / Q000097:blood / Q000493:pharmacokinetics; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D008075:Lipoproteins, HDL / Q000097:blood* / Q000493:pharmacokinetics; D008593:Menopause / Q000097:blood*; D008657:Metabolic Clearance Rate / Q000187:drug effects; D008875:Middle Aged
D002914:Chylomicrons; D007457:Iodine Radioisotopes; D008075:Lipoproteins, HDL; D004958:Estradiol